Growth in Children with Chronic Lung Disease

Publisher Website
Google Scholar
Abstract
In patients with cystic fibrosis, the inflammatory response in the airways to bacterial infection is excessive and deleterious. Thus, interrupting the inflammatory response is a goal of therapy. In a clinical trial of prednisone, given on alternate days at a dose of either 1 or 2 mg per kilogram of body weight to patients 6 to 14 years of age who had cystic fibrosis and mild-to-moderate lung disease, pulmonary function was significantly better in the group that received 1 mg of prednisone per kilogram than in the placebo group.1 However, prednisone treatment also caused diabetes, cataracts, and growth retardation at . . .